AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03766256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making with pharmacists
Description: Pharmacist will engage patient with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
Study NCT01843543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Course
Description: The MBSR course developed by Jon Kabat-Zinn is a mind-body intervention that incorporates mindfulness techniques. This is an eight week MBSR course at OHSU. Class instruction will be augmented by daily home practices of listening to audiotapes, diary reflections, and reading preloaded on itouch devices provided to participants. Adherence will be assessed through in-house iMINDr tracking program loaded on the itouch.
Study NCT00822081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination
Description: 1 drop BID in each eye
Study NCT00822081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination
Description: 1 drop BID in each eye
Study NCT00822081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.
Description: 1 drop BID in each eye
Study NCT00822081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
Description: 1 drop BID in each eye
Study NCT00908401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastmilk
Description: Breastmilk: 0.2 ml
Study NCT00908401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sucrose
Description: oral sucrose: 0.2 ml one time 1 minute before the painful procedure with a pacifier
Study NCT04787406 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30 second ramp up period prior to the specified stimulation period and phased-out with a ramp down of the current following the specified stimulation period. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off for during the specified stimulation period.
Study NCT03383393 — intervention group
Intervention type: DRUG
Intervention: Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)
Description: intracoronary drugs
Study NCT00002583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 50 mg/m2 IV
Study NCT00002583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine ditartrate
Description: 25 mg/m2 IV
Study NCT02867904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg depomedrol, 1ml, injection)
Description: Experimental Drug
Study NCT02867904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marcaine (4ml 0.5%, injection)
Description: Control
Study NCT02867904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine (4ml 0.5%, injection)
Description: Control
Study NCT00907842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parietex Parastomal Mesh
Description: mesh placed intraperitoneally around the stoma
Study NCT00976235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT - Implantable Miniature Telescope
Description: Implantation of the telescope prosthesis (performed under the initial study)
Study NCT04523558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of LuxSmart hydrophobic IOLs (Bausch + Lomb) in both eyes
Description: Extended depth of field intraocular lens made form hydrophobic material
Study NCT00886665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, 4 g, powder, oral, 3 times a day
Study NCT00886665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JWHGWT
Description: JWHGWT, 4 g, powder, oral, 3 times a day
Study NCT04156269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-CS1 cCAR T cells
Description: BCMA-CS1 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study NCT03525548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-445/TEZ/IVA
Description: Participants received VX-445/TEZ/IVA orally once daily in the morning.
Study NCT03525548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Participants received TEZ/IVA orally once daily in the morning.
Study NCT03525548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Participants received IVA orally once daily in the evening.
Study NCT03525548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Participants received IVA orally once daily in the evening.
Study NCT03525548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to VX-445/TEZ/IVA orally once daily in the morning.
Study NCT03525548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received placebo matched TEZ/IVA orally once daily in the morning.
Study NCT00628797 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVA1
Description: intraindividual half body irradiation
Study NCT00628797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UVA1
Description: 60 J/cm2 at least 36 tx
Study NCT00628797 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: UVA1
Description: 60 J/cm2 at least 36 tx
Study NCT02094014 — intervention group
Intervention type: BEHAVIORAL
Intervention: Normal Auditory Feedback
Description: Participants will produce sentences under normal speaking conditions, able to hear their own speech.
Study NCT02094014 — intervention group
Intervention type: BEHAVIORAL
Intervention: Masked Auditory Feedback
Description: Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.
Study NCT02094014 — intervention group
Intervention type: BEHAVIORAL
Intervention: Altered Auditory Feedback
Description: Participants will produce sentences while listening to their speech shifted up one octave and delayed.
Study NCT04421222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Once daily dose of abiraterone acetate
Study NCT03152955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be applied in patient-controlled analgesia.
Study NCT03152955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scalp nerve block
Description: Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.
Study NCT03152955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
Study NCT03152955 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ondansetron
Description: Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
Study NCT03152955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
Study NCT03152955 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
Study NCT03331484 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor
Description: Ticagrelor 90 mg twice daily
Study NCT03331484 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban
Description: Rivaroxaban 15 mg once daily (10mg for patients with moderate renal impairment, creatinine clearance: 30-50 mL/min by the Cockcoft Gault method)
Study NCT02295514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PTP1B dosage
Description: PTP1B sampled and dosed during sepsis
Study NCT01551602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate
Study NCT01551602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-10-T
Description: subcutaneous administration of teriparatide acetate
Study NCT01551602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple administration of placebo AK159
Study NCT03917004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: The starting rate of nitroglycerin was 0.25 μg / kg / min and the mean arterial pressure (MAP) decreased to 80% of the baseline but not less than 70%.The drug infusion rate was adjusted so that the MAP was maintained in the range to the suture, and the administration was stopped and the blood pressure was gradually returned to the pre-depressurization level.
Study NCT01662063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
Study NCT02127086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The PAIN Algorithm and analgesic order sets to be used by nurses to assess and reassess pain and opioid-related side effects will include orders for: 1) managing pain based on MOPAT Behavioral Dimension cut scores, 2) pre-medication before painful procedures, 3) titration of drugs, and 4) managing major opioid side effects. The order sets will start with small doses of opioids that will be titrated upwards for peak analgesic effect and allow for adjustment for patient characteristics and type of pain while simultaneously monitoring for and treating side effects.
Study NCT04543006 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: serology
Description: blood sample of 10 ml twice (6 and 12 months after the Covid-19)
Study NCT01266499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: will not receive PO treatment
Description: will not receive PO treatment - will receive plecebo treatment
Study NCT01266499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Garamycin 80mg x 4/d
Description: PO Garamycin 80mg x 4/d
Study NCT01740999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: silicone arthroplasty
Description: silicone arthroplasty
Study NCT01740999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrodesis
Description: arthrodesis
Study NCT01894256 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablet dosing
Description: Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
Study NCT02511171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranial osteopathic manipulative therapy
Study NCT00314925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seneca Valley Virus (biological agent)
Description: Dose escalation (starting at 1 × 10\^7 vp/kg), IV (in the vein) over 1 hour in a single administration
Study NCT05181514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% Intralipid
Description: Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of 20% fat emulsion (Intralipid 20%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
Study NCT05181514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of normal saline (Sodium Chloride 0.9%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
Study NCT03215901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Beautiful Future Video
Description: Video delivering information on the longevity gains due to HIV treatment in the area.
Study NCT03215901 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Active Control Video
Description: Video on another topic.
Study NCT03889626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 500mg qd po, q4w
Study NCT03889626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 bid po, d1-14, q3w
Study NCT03117595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: Dosages as previously written
Study NCT03117595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl morphine
Description: Dosage as previously written
Study NCT02207062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02207062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02923739 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study NCT02923739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02923739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Description: Given IV
Study NCT02923739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02923739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02923739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT02923739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02923739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04026165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SEL
Description: Tablet administered orally once daily
Study NCT04026165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Tablet administered orally once daily
Study NCT04026165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet administered orally once daily
Study NCT04026165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet administered orally once daily
Study NCT02179502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690 single ascending doses
Description: Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
Study NCT02179502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single ascending doses
Description: Single dose, oral suspension or solid formulation matching placebo
Study NCT02179502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690, multiple ascending doses, oral suspension
Description: Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
Study NCT02179502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, multiple ascending doses, oral suspension
Description: Multiple doses, daily for 14 days, oral suspension matching placebo
Study NCT02929433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycloergometer
Description: Daily training of the RCT patients was provided by the use of a cycloergometer at home. Educational support once a month was guaranteed by a nurse of the telemedicine service
Study NCT04387630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral hypoglycemic drug. Initial dose 500-850 mg/d. incrementally increased to a maximum daily dose of 2550 mg in three divided doses.
Study NCT04387630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Simethicone 60 mg three times daily.
Study NCT02573402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation
Description: 10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.
Study NCT02573402 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: 10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
Study NCT02623855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family outings
Description: Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.
Study NCT02623855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Park prescription
Description: Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
Study NCT02623855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Park prescription
Description: Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
Study NCT02623855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedometry
Description: Participants will record their daily pedometry.
Study NCT02623855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometry
Description: Participants will record their daily pedometry.
Study NCT02623855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
Study NCT05264532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information-graphic video
Study NCT05264532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive family letter
Study NCT05264532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05264532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03155620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT02552693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced training, supervision and support
Description: The intervention includes the following activities:~Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities.
Study NCT03465670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CHX
Description: Patients received a 21-day supply of 0.2% chlorhexidine (CHX) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.